Increasing cure rates of solid tumors by immune checkpoint inhibitors

Immunotherapy has become the central pillar of cancer therapy. Immune checkpoint inhibitors (ICIs), a major category of tumor immunotherapy, reactivate preexisting anticancer immunity. Initially, ICIs were approved only for advanced and metastatic cancers in the salvage setting after or concurrent w...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Weijie, Xue, Ruobing, Zhu, Zheng, Farrukh, Hizra, Song, Wenru, Li, Tianhong, Zheng, Lei, Pan, Chong-xian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843946/
https://www.ncbi.nlm.nih.gov/pubmed/36647169
http://dx.doi.org/10.1186/s40164-023-00372-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843946/
https://www.ncbi.nlm.nih.gov/pubmed/36647169
http://dx.doi.org/10.1186/s40164-023-00372-8

Ejemplares similares